RSS-Feed abonnieren
DOI: 10.1055/a-1494-3623
Pyrrolizidine Alkaloid Contamination in Medicinal Plants: Regulatory Requirements and Their Impact on Production and Quality Control of Herbal Medicinal Products
Abstract
Against the background of potential contamination of medicinal plant materials with pyrrolizidine alkaloids caused by weeds, suppliers of herbal drugs and manufacturers of herbal medicinal products have taken action by establishing a Code of Practice by monitoring potential contamination and by collection of data. In August 2020, the Herbal Medicinal Products Committee, in its new draft public statement, proposed a daily intake of 1.0 µg of pyrrolizidine alkaloids per day for adults in general, also including contaminations of herbal medicinal products. Over the past years, the results of data collections showed a remarkable reduction of the pyrrolizidine alkaloid burden in herbal drugs and herbal extracts. Meanwhile, a stable situation has been achieved for herbal drugs, while further improvement can be observed for herbal extracts. The results indicate that the implemented measures have been efficient and contribute to a continuous and sustainable reduction of pyrrolizidine alkaloid contamination. A permanent limit of 1.0 µg of pyrrolizidine alkaloids per day is considered appropriate to guarantee sufficient availability of batches used for the production of herbal medicinal products. The new Ph.Eur. general chapter 2.8.26 describes, as an example, an analytical procedure suitable for the determination of target pyrrolizidine alkaloids.
Key words
pyrrolizidine alkaloids - herbal medicinal products - contamination - limits - Code of PracticePublikationsverlauf
Eingereicht: 27. Januar 2021
Angenommen nach Revision: 19. April 2021
Artikel online veröffentlicht:
26. Mai 2021
© 2021. Thieme. All rights reserved.
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
-
References
- 1 BfR (German Federal Institute for Risk Assessment). Pyrrolizidine alkaloids in herb teas and teas. Statement 018/2013 of the BfR of 5 July 2013. Accessed March 15, 2021 at: https://mobil.bfr.bund.de/cm/343/pyrrolizidinalkaloide-in-kraeutertees-und-tees.pdf
- 2 Dittrich H, Hösel K, Sievers H, Klier B, Waimer F, Heuberger H, Plescher A, Armbrüster N, Steinhoff B. Code of Practice zur Vermeidung und Verringerung von Kontaminationen pflanzlicher Arzneimittel mit Pyrrolizidinalkaloiden. Pharmazeutische Industrie 2016; 78: 836-845
- 3 [Anonymous] Code of practice to prevent and reduce pyrrolizidine alkaloid contaminations of medicinal products of plant origin. Accessed March 15, 2021 at: http://www.journals.elsevier.com/journal-of-applied-research-on-medicinal-and-aromatic-plants/news
- 4 Herbal Medicinal Products Committee (HMPC). Public statement on contamination of herbal medicinal products/traditional herbal medicinal products with pyrrolizidine alkaloids – Transitional recommendations for risk management and quality control (EMA/HMPC/328782/2016). Accessed March 15, 2021 at: https://www.ema.europa.eu/documents/public-statement/public-statement-contamination-herbal-medicinal-products/traditional-herbal-medicinal-products-pyrrolizidine-alkaloids_en.pdf
- 5 Herbal Medicinal Products Committee (HMPC). Public statement on the use of herbal medicinal products containing toxic, unsaturated pyrrolizidine alkaloids (PAs). Final. Accessed March 15, 2021 at: https://www.ema.europa.eu/documents/public-statement/public-statement-use-herbal-medicinal-products-containing-toxic-unsaturated-pyrrolizidine-alkaloids_en.pdf
- 6 Committee on Herbal Medicinal Products (HMPC). Draft Public statement on the use of herbal medicinal products containing toxic, unsaturated pyrrolizidine alkaloids (PAs) including recommendations regarding contamination of herbal medicinal products with pyrrolizidine alkaloids (EMA/HMPC/893108/2011 Rev. 1). Accessed March 15, 2021 at: https://www.ema.europa.eu/documents/public-statement/draft-public-statement-use-herbal-medicinal-products-containing-toxic-unsaturated-pyrrolizidine_en-0.pdf
- 7 EFSA Panel on Contaminants in the Food Chain (CONTAM). Risks for human health related to the presence of pyrrolizidine alkaloids in honey, tea, herbal infusions and food supplements. EFSA J 2017; 15: 4908-4943
- 8 European Commission. Commission Regulation (EU) 2020/2040 of 11 December 2020 amending Regulation (EC) No 1881/2006 as regards maximum levels of pyrrolizidine alkaloids in certain foodstuffs. Official Journal of the European Union. 14 December 2020. Accessed March 15, 2021 at: https://eur-lex.europa.eu/legal-content/EN/TXT/HTML/?uri=CELEX:32020R2040&qid=1620204015469&from=EN
- 9 Steinhoff B. Pyrrolizidine alkaloid contamination in herbal medicinal products: Limits and occurrence. Food Chem Toxicol 2019; 130: 262-266
- 10 BfR (German Federal Institute for Risk Assessment). Determination of pyrrolizidine alkaloids (PA) in botanical substances using SPE-LC-MS/MS. Description of the method. BfR-PA-Tee-2.0/2014. Accessed March 15, 2021 at: http://www.bfr.bund.de/cm/343/bestimmung-von-pyrrolizidinalkaloiden.pdf
- 11 European Pharmacopoeia. Chapter 2.8.26. Contaminant pyrrolizidine alkaloids (draft). Pharmeuropa 32.1 (December 2019).